Chesapeake — Shareholder Meeting (April 2007)
24 slides from Chesapeake's shareholder meeting presentation, Apr 30, 2007
Slide 1: Chesapeake Annual Meeting
April 25, 2007 Chesapeake Annual Meeting
Slide 2: Financial Highlights
Financial Highlights • Net sales decr eas ed 1% to $995.4 million Operating income* of $44.9 million compared to $47.7 million in 2005 • • Reported net loss per share of $1.67 Excludes gains or losses on divestitures, impairment and restructuring charges, and loss on extinguishment of debt. *
Slide 3: Earnings Per Share: Reconciliation of Reported to Adjusted EPS
Earnings Per Share Reconciliation of Reported to Adjusted EPS
Slide 4: Operating Income vs. 2006
* Excludes gains or losses on divestitures and impairment, restructuring costs and loss on extinguishment of debt. Operating Income* ($ in millions) vs. 2006
Slide 5: Proactive Management of Pension Obligations
• U.S. defined benefit plan benefits frozen; U.S. qualified plan fully funded • U.K. plan closed to new entrants • Incremental total funding in 2004-2006 of $35 million • Total plan deficits reduced from $153 million at YE 2005 to $96 million at YE • Future improvements expected Proactive Management
Slide 6: $25-Million Cost Savings Program
$25-Million Cost Savings Program • $16 million in annualized savings to date • Closed three plants: – Birmingham, England – Bedford, England – Ezy sur Eure, France • Sold French luxury packaging business • Sold plastics operation in Northern Ireland
Slide 7: Operational Excellence & Cost Savings News
Operational Excellence & @ichesapeake" Cost Saving News f = be Ss Chesapeake
Slide 8: Growth Initiatives
Growth Initiatives “As important as continuous cost savings are to our organization, I want to assure you that we understand that a vibrant organization needs growth as well to be successful.” 4 th Quarter Earnings Conference Call
Slide 9: Blue Chip Pharma Customers
Blue Chip Pharma Customers
Slide 10: Braille Pharma Packs
Braille Pharma Packs
Slide 11: Anti-Counterfeiting Solutions
Anti-Counterfeiting Solutions
Slide 12: New China Paperboard Plant
New China Paperboard Plant • Enables growth opportunities in Pharma • World-Class facility • Offers anti-counterfeiting solutions
Slide 13: SPARK High
IGuian SPARK High Chesapeake’
Slide 14: East Kilbride Modernization
East Kilbride Modernization
Slide 15: Lithoprint Relocation
Lithoprint Relocation • State-of-the-art facility for alcoholic drinks labels • Enthusiastic customer response
Slide 16: Agrochemical Twinpack
Agrochemical Twinpack
Slide 17: Hungarian Joint Venture
Hungarian Joint Venture • Will produce large specialty plastic containers for agrochemicals and specialty chemicals markets • Supporting major contract with Syngenta • Near Budapest with established JV partner
Slide 18: African Operations
Cape Town Harrismith Mauritius African Operations
Slide 19: #1 Focus -- Increase Cash Flow and Profitability
Cost Savings Program - $25 million Organic Growth - Worldwide pharmaceutical packaging demand expected to grow 5% per year to 2009, CSK position with majority of top 20 global pharmaceutical companies Strategic Initiatives - Arlington Press, South Africa, China, Hungarian JV Increased Cash Flow & Pr
Slide 20: Operating Earnings
Operating Earnings “We are convinced we are making the right moves; however, an improvement in operating earnings, exclusive of costs associated with our global cost savings program, will be a challenge in 2007.” 4 th Quarter Earnings Conference Call
Slide 21: Thank you for your continued support
Thank you for your continued support.
Slide 22: Non-GAAP Financial Measures
xzzzzz Non-GAAP Financial Measures Operating income from continuing operations, in each case exclusive of losses associated with the extinguishments of debt, restructuring expenses, asset impairments, gains or losses on divestitures, and goodwill impairment are non-GAAP financial measures. The compa
Slide 23: Reconciliation of Non-GAAP Financial Measures
Disclaimer Full Year RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ($ in millions) Operating (loss) income $ 0.3 $ (277.8 ) Add: goodwill impairment charge $ 14.3 $ 312.0 Add: restructuring expenses, asset impairments and other exit costs $ 33.4 $ 10.7 Less/Add: (gain) loss on divestitures $ (3.1 )
Slide 24: Chesapeake Annual Meeting
April 25, 2007 Chesapeake Annual Meeting